Baillie Gifford & CO Halozyme Therapeutics, Inc. Transaction History

Baillie Gifford & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$38.53 - $51.78 $2,003 - $2,692	-52 Reduced 6.38%	763 $30,000
Q2 2022 Aug 08, 2022	BUY	$37.35 - $48.3 $1,344 - $1,738	36 Added 4.62%	815 $36,000
Q4 2021 Jan 20, 2022	SELL	$31.82 - $40.75 $3,213 - $4,115	-101 Reduced 11.48%	779 $31,000
Q3 2021 Oct 19, 2021	SELL	$38.47 - $46.42 $3,154 - $3,806	-82 Reduced 8.52%	880 $36,000
Q2 2021 Aug 02, 2021	SELL	$38.84 - $51.31 $1,708 - $2,257	-44 Reduced 4.37%	962 $44,000
Q1 2021 May 06, 2021	BUY	$39.51 - $51.45 $2,054 - $2,675	52 Added 5.45%	1,006 $42,000
Q4 2020 Feb 10, 2021	BUY	$25.81 - $43.62 $24,622 - $41,613	954 New	954 $41,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.